Praecis Pharmaceuticals Incorporated

FDA lifts clinical hold on PPI-2458 trial in non-Hodgkin lymphoma

Published in Food and Drug Law Weekly, July 30th, 2004

Praecis Pharmaceuticals Incorporated (PRCS) has received clearance from the U.S. Food and Drug Administration (FDA) to resume its phase I clinical trial of PPI-2458 in non-Hodgkin lymphoma (NHL).

The company previously reported that the FDA had issued a clinical hold based upon a preliminary neuropathological finding in an animal safety study.

Since that time, Praecis has been working to resolve the issue by further elucidating the nature of the original finding in several completed and ongoing animal studies, and by modifying its clinical plan.

Praecis has been notified by the FDA that the clinical hold issues have been...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly

Source: Food and Drug Law Weekly (2004-07-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry